In melanoma pretreatment tumors, CD4+ T cells from nonresponders had significantly higher activation (for example, TIMD4/TIM3, OX40/EBI3, HLA) and cell cycle cGEP usage (P < 0.05 two-tailed t-test; Fig. 6b and Supplementary Table 8). This evidence concerns the gene HAVCR2 and melanoma.